300199.SZ
翰宇药业
SZSE · Healthcare · C 制造业 · CN
CNY 22.17
−4.03%Aug 20, 2026, 12:29 UTC
Hybio Pharmaceutical announced its 2026 first-half results: net profit attributable to shareholders was 237 million yuan, up 62.72% year-on-year; revenue was 688 million yuan, up 25.27% year-on-year.
Source:Aug 12, 2026, 13:20 UTC
Hanyu Pharmaceutical signed a cooperation agreement with Sansheng Mandi for semaglutide injection (blood glucose control indication).
Source:Aug 12, 2026, 10:26 UTC
Hybio Pharmaceutical signed a cooperation agreement with Sansheng Mandi regarding semaglutide injection.
Aug 7, 2026, 08:40 UTC
Hybio Pharmaceutical announced that its first generic filing for the tirzepatide injection has been accepted by the National Medical Products Administration, becoming the first domestic company to submit such an application.
Source:Jul 29, 2026, 10:05 UTC
HanYu Pharmaceutical announced that its new GLP-1/GIP/GCGR triple receptor agonist HY3003 injection has completed preclinical animal pharmacodynamic studies.
Source:Jul 6, 2026, 11:10 UTC
Han Yu Pharmaceutical's wholly-owned subsidiary Han Yu Pharmaceutical (Wuhan) Co., Ltd. received approval from the National Medical Products Administration for the marketing of its chemical active pharmaceutical ingredient liraglutide (H).
Source:Jul 3, 2026, 08:52 UTC
The China National Medical Products Administration's Drug Evaluation Center accepted the marketing authorization application for semaglutide injection (weight loss indication) filed by Sansheng Mandi, a partner of Hybio Pharmaceutical.
Source: